Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AIM Vaccine Co's Enterprise Value is HK$4,046 Mil.
AIM Vaccine Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-764 Mil. Therefore, AIM Vaccine Co's EV-to-EBIT ratio for today is -5.29.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, AIM Vaccine Co's Enterprise Value is HK$4,046 Mil.
AIM Vaccine Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-589 Mil. Therefore, AIM Vaccine Co's EV-to-EBITDA ratio for today is -6.87.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, AIM Vaccine Co's Enterprise Value is HK$4,046 Mil.
AIM Vaccine Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was HK$1,125 Mil. Therefore, AIM Vaccine Co's EV-to-Revenue ratio for today is 3.60.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, AIM Vaccine Co's Enterprise Value is HK$4,046 Mil.
AIM Vaccine Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-61 Mil. Therefore, AIM Vaccine Co's EV-to-FCF ratio for today is -66.32.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
AIM Vaccine Co (HKSE:06660) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
AIM Vaccine Co's current Enterprise Value is HK$4,046 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. AIM Vaccine Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-764 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
AIM Vaccine Co's current Enterprise Value is HK$4,046 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. AIM Vaccine Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-589 Mil.
AIM Vaccine Co's current Enterprise Value is HK$4,046 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. AIM Vaccine Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was HK$1,125 Mil.
AIM Vaccine Co's current Enterprise Value is HK$4,046 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. AIM Vaccine Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was HK$183 Mil.
AIM Vaccine Co's current Enterprise Value is HK$4,046 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. AIM Vaccine Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM Vaccine Co Enterprise Value Related Terms
AIM Vaccine Co Enterprise Value Historical Data
* Premium members only.
The historical data trend for AIM Vaccine Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06660 vs VRTX, REGN, MRNA: Enterprise Value Comparison
For the Biotechnology subindustry, AIM Vaccine Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM Vaccine Co Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM Vaccine Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where AIM Vaccine Co's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
AIM Vaccine Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$4,046 Mil mean?
AIM Vaccine Co (HKSE:06660) has a Enterprise Value of HK$4,046 Mil as of Sep. 14, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on AIM Vaccine Co and its competitors.
Is AIM Vaccine Co's Enterprise Value too high?
AIM Vaccine Co's current Enterprise Value is HK$4,046 Mil. Overall, AIM Vaccine Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM Vaccine Co's Enterprise Value compare to VRTX and REGN?
AIM Vaccine Co's Enterprise Value of HK$4,046 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on AIM Vaccine Co and its competitors. AIM Vaccine Co's current Enterprise Value is HK$4,046 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM Vaccine Co stock overvalued right now?
Based on GuruFocus' analysis, AIM Vaccine Co (HKSE:06660) is currently considered Possible Value Trap. The stock's GF Value™ is HK$4.08, compared to a current price of HK$1.63 — trading 60.2% below its estimated fair value. The current Enterprise Value is HK$4,046 Mil. AIM Vaccine Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For AIM Vaccine Co (HKSE:06660), the current Enterprise Value is HK$4,046 Mil as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM Vaccine Co (HKSE:06660) Overvalued in 2026?
Based on GuruFocus' analysis, AIM Vaccine Co stock appears to be undervalued.
The current stock price of HK$1.63 is trading 60.2% below its estimated GF Value™ of HK$4.08.
GuruFocus considers AIM Vaccine Co to be Possible Value Trap.
Key valuation signals for HKSE:06660:
Enterprise Value: HK$4,046 Mil
GF Value™: HK$4.08 vs. price of HK$1.63 (60.2% below fair value)
No single metric tells the full story. See the HKSE:06660 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM Vaccine Co Ltd is a China-based full-chain vaccine company engaged in the research and development, manufacturing, and commercialization of vaccine products. The company's commercialized products include recombinant HBV vaccines, freeze-dried human rabies vaccines, inactivated HAV vaccines, Group A, C, Y, and W135 meningococcal polysaccharide vaccines, bivalent inactivated HFRS vaccines, and mumps vaccines. The company generates the majority of its revenue from the PRC.
61GF Score
Get the complete analysis for HKSE:06660
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06660 has been successfully added to your 
